Alzheimer’s disease is the most common form of dementia and the sixth-leading cause of death in the United States. The text says 5.4 million Americans have Alzheimer’s disease and projects that number will reach 16 million by 2050; it also projects a fourfold increase worldwide over 35 years.
T3D Therapeutics has an exclusive, worldwide license for T3D-959 and structurally-related small molecules. Their mechanism of action may provide therapeutic benefit in neurodegenerative diseases such as Alzheimer’s Disease (AD) and Huntington’s Disease (HD).
T3D Therapeutics is developing T3D-959 as a potential disease-modifying treatment for Alzheimer’s disease, with the potential to slow, stop, or reverse its course.
T3D Therapeutics is developing T3D-959 as a potential disease-modifying treatment for Alzheimer’s disease. It has initiated preclinical studies of T3D-959 in Huntington’s disease models.
T3D Therapeutics, Inc. was founded in 2013 and is developing a drug for Alzheimer’s disease. It is also targeting other neurodegenerative diseases, with an emphasis on Huntington’s disease.